BOSTON --(BUSINESS WIRE)--Jan. 7, 2021-- Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller , Ph.D., chief
BOSTON --(BUSINESS WIRE)--Jan. 5, 2021-- Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul , M.D., chief executive
